Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 1, 2004, Pages 259-262

  Cha, Raymond ^a,b   Rybak, Michael J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Albumin; Antimicrobials; Bacteria; Cyclic lipopeptides; Resistance

Indexed keywords

CALCIUM; DAPTOMYCIN; HUMAN ALBUMIN; METICILLIN; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG PROTEIN BINDING; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PH; PROCESS MODEL; STATISTICAL ANALYSIS;

ANTI-BACTERIAL AGENTS; CULTURE MEDIA; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; SERUM ALBUMIN; SERUM BACTERICIDAL TEST; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 3543132567     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh259     Document Type: Article

References (10)

1. Akins, R. L. & Rybak, M. J. (2000). In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrobial Agents and Chemotherapy 44, 1925-9.
2. Tally, F. P. & Debruin, M. F (2000). Development of daptomycin for gram-positive infections. Journal of Antimicrobial Chemotherapy 46, 523-6.
3. Brier, G. L., Wolny, J. D. & Black, H. R. (1989). Protein binding of daptomycin. In Programs and Abstracts of the Twenty-ninth Interscience, Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, 1989. Abstract 1347. p. 329. American Society for Microbiology, Washington, DC, USA.
4. Louie, A., Kaw, P., Liu, W. et al. (2001). Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrobial Agents and Chemotherapy 45, 845-51.
5. Lamp, K. C., Rybak, M. J., Bailey, E. M. et al. (1992). In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrobial Agents and Chemotherapy 36, 2709-14.
6. Bailey, E. M., Rybak, M. J. & Kaatz, G. W. (1991). Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrobial Agents and Chemotherapy 35, 1089-92.
7. Davidson, R. J., Zhanel, G. G., Phillips, R. et al. (1991). Human serum enhances the postantibiotic effect of fluoroquinolones against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 35, 1261-3.
8. Stanley, D., McGrath, B. J., Lamp, K. C. et al. (1994). Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus. Pharmacotherapy 14, 35-9.
9. Akins, R. L. & Rybak, M. J. (2001). Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrobial Agents and Chemotherapy 45, 454-9.
10. Cha, R. & Rybak, M. J. (2003). Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrobial Agents and Chemotherapy 47, 1598-603.